Autolus Therapeutics Unveils New Clinical Abstract
Autolus Therapeutics plc (NASDAQ: AUTL), a forward-thinking biopharmaceutical company, has recently announced an exciting development regarding its next-generation programmed T cell therapies. This important update comes ahead of the American College of Rheumatology (ACR) Convergence 2025, an event scheduled for late October. At this prestigious gathering, Autolus will showcase an abstract that details the promising stimuli observed from their CARLYSLE study, which targets severe refractory systemic lupus erythematosus (srSLE).
Conference Presentation Details
The presented abstract is number 2458, featuring the title: "Obecabtagene autoleucel (obe-cel), a CD19-targeting autologous chimeric antigen receptor T-cell therapy (CAR T) with a fast off-rate binding domain, in patients with severe, refractory systemic lupus erythematosus (srSLE): preliminary results from the Phase I CARLYSLE study." The presentation is set for Tuesday, October 28, 2025, between 10:30 AM and 12:30 PM Central Time, with Dr. Maria Leandro as the presenting author.
Key Findings from the CARLYSLE Study
Initial analyses from the CARLYSLE study indicate a favorable safety profile for obe-cel. There have been no identified dose-limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), nor any severe cytokine release syndrome (CRS). Moreover, all participants exhibited a reduction in SLEDAI-2K scores alongside notable clinical benefits. Particularly encouraging are reports that three patients achieved a complete renal response, highlighting the potential of obe-cel as an effective treatment option for srSLE patients. Further comprehensive data will be divulged during the conference.
About Autolus Therapeutics
Autolus Therapeutics plc specializes in developing cutting-edge T cell therapies, working to translate innovative research into therapies for combating cancer and autoimmune illnesses. Utilizing a suite of proprietary T cell programming technologies, the company customizes T cell therapies that can efficiently recognize and eliminate target cells, overcoming existing defense mechanisms. Additionally, Autolus has a commercial therapy known as AUCATZYL and is actively progressing various candidates aimed at treating hematological malignancies and solid tumors.
Looking Ahead
As Autolus Therapeutics prepares for its upcoming presentation at ACR Convergence 2025, the company continues to focus on advancing the future of T cell therapy through its innovative research. This commitment promises to play a crucial role in improving the treatment landscape for patients with challenging medical conditions like srSLE.
Frequently Asked Questions
What is the CARLYSLE study?
The CARLYSLE study is a clinical trial assessing the efficacy and safety of obe-cel, a CAR T-cell therapy aimed at treating severe refractory systemic lupus erythematosus (srSLE).
What will be presented at the ACR Convergence 2025?
Autolus Therapeutics will present updated findings from the CARLYSLE study, including safety profiles and clinical outcomes observed in patients treated with obe-cel.
Who is the presenting author for the conference?
Dr. Maria Leandro will be presenting the findings at the ACR Convergence 2025 event.
What is obe-cel?
Obe-cel is an innovative CD19-targeting autologous chimeric antigen receptor T-cell therapy designed for patients with challenging conditions like srSLE.
How does Autolus Therapeutics contribute to T cell therapy?
Autolus Therapeutics leverages proprietary technologies to engineer highly targeted T cell therapies that are designed to effectively treat various forms of cancer and autoimmune diseases.
